MC Healthcare Ventures
Corporate VCActively deployingCambridge · Seed–Series A · 3 people tracked
Investment thesis
The firm invests in seed and early-stage biotechnology companies, primarily located in North America and Europe. It targets companies developing novel therapeutics, platform technologies, diagnostics, and vaccines. Areas of interest include platform technologies such as regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine; novel therapeutics addressing neurodegeneration, immunology, inflammation, and rare disease; and diagnostics for neurodegenerative disorders. As the corporate venture group of Tanabe Pharma Corporation, it offers portfolio companies both large-company resources and small-firm attention. Its team of PhDs supports biotech entrepreneurs in bringing products to market.
Source: firm website, verified Aug 3, 2026.
Team · 3 people
from public directories
What they invest in
from 16 of 48 portfolio companiesBiotech ×15Deep Tech ×6Healthtech ×3AI & Machine Learning ×2Digital Health ×1Medical Devices ×1
HQs:United States×10Japan×1
Investments · 48 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 22021 · 12019 · 16 dated
RNA-editing therapeutics company using its OPERA technology platform.
BiotechCambridge, US
Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)Jean-Francois Formela(Director)
Discovers and develops microRNA-targeting therapies for areas of high unmet medical need.
BiotechBoulder, US
Thomas Hughes(Director)Marvin Caruthers(Director)Christopher J Morl(Executive Officer)Bruce Booth(Executive Officer, Director)Jason A. Leverone(Executive Officer)David Rodman(Executive Officer)
BiotechLondon
James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)
BiotechWaltham, US
Errik B. Anderson(Executive Officer, Director)Piotr Bobrowicz(Executive Officer, Director)Jay Rosanelli(Executive Officer)Fabian Hansen(Director)
BoardAnthony Sun(Director)
Board seatAlaa Halawa· per SEC Form D · $40M raise · filed Apr 2026
San Francisco, US
Board seatAlaa Halawa· per SEC Form D · filed Oct 2025
A clinical-stage biotechnology company focused on therapies for vision-threatening conditions including wet AMD and diabetic macular edema.
Austin, US
Board seatAlaa Halawa· per SEC Form D · $330M raise · filed Jun 2026
BiotechHealthtechDurham, US
William Roy Smythe(Executive Officer, Director)Xiling Shen(Executive Officer, Director, Promoter)David Shiaowen(Director)
BoardJohn de Koning(Director)
Board seatAlaa Halawa· per SEC Form D · $19.4M raise · filed Apr 2025
Spin-out of Forge Therapeutics pioneering a metalloenzyme chemistry platform for immuno-oncology and inflammation medicines.
Blacksmith Medicines operates a drug discovery platform focused on developing medicines that target human metalloenzymes.
BiotechDeep Tech
Capsigen engineers customized AAV (adeno-associated virus) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE) screening platform and data science to deliver gene therapies to specific target cells.
AI & Machine LearningBiotechHealthtechVancouver, US
John(Chief Executive Officer)Charlie(Chief Business Officer)
Developed next-generation protein drugs for inflammatory diseases and cancer; acquired by J&J in 2014.
Developed a platform for targeted protein degradation of extracellular and membrane-bound proteins.
Developed RNA/DNA editing technology using PPR proteins for pharma, agriculture, and biomanufacturing.
Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.
Uses a novel drug discovery platform to develop first-in-class therapeutics against metalloprotein targets.
Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes.
BiotechDeep Tech
Genkyotex was a developer of NOX inhibitor therapeutics, now owned by Calliditas Therapeutics AB.
Biotech
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
BiotechCambridge, US
Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)Michael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Ronald Cooper(Director)
Developed RNAi therapeutics; merged with Silence Therapeutics in December 2009.
Platform technology to identify therapeutics that selectively target the protein degradation pathway.
Unlocking chemical space to develop novel, complex 3D small molecule drugs.
Diagnostics company focused on low-abundance protein biomarkers; merged with a Biocartis division to form MyCartis in 2014.
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Co-founder)Roet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)Shafique Virani(Executive Officer)Jason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)
BiotechGreenville, US
Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)Kevin Weeks(Executive Officer, Director)John Gustofson(Director)
BoardMike Dial(Director)
Biopharmaceutical company targeting RIG-I for immune-mediated treatment of cancer and viral diseases; acquired by Merck in 2017.
Uses its JUMP70 chaperone platform to develop therapeutics for neurodegenerative diseases like ALS and Huntington's.
SOLA Biosciences develops gene therapies for conformational diseases, using its JUMP70 platform to activate the body's protein-folding machinery to refold or remove misfolded proteins.
BiotechDeep Tech
Developing a voice-based technology platform to monitor and diagnose psychological and physical conditions.
Sonde provides an API/SDK platform that analyzes vocal biomarkers to detect health signals from voice, offering insights into users' mental, cognitive, and respiratory fitness.
AI & Machine LearningDigital HealthHealthtech
Developed drugs targeting the interface between inflammatory and metabolic pathways via adaptive ER responses.
Clinical-stage company developing targeted therapies for kidney disease.
Developed a novel TPD technology for selective degradation of aggregated proteins in neurodegenerative disease.
LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.
BiotechDeep Tech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 7
IPOs and acquisitions across the tracked portfolioKorro BioNASDAQ: KRROmiRagen TherapeuticsNASDAQ: VRDNSilence TherapeuticsNASDAQ: SLNCovagen AGacq. by Johnson & JohnsonFerroKin Biosciencesacq. by ShireIntradigm Corporationacq. by Silence TherapeuticsRigontecacq. by Merck
Portfolio news
latest coverage across their companiesQuralis · nasdaqprivatemarket.com · Apr 3, 2026
Frequently asked questions
- What stage does MC Healthcare Ventures invest at?
- MC Healthcare Ventures invests at the Seed, Series A stages.
- What sectors does MC Healthcare Ventures focus on?
- MC Healthcare Ventures focuses on Biotech, Healthtech, Medical Devices.
- Where is MC Healthcare Ventures located?
- MC Healthcare Ventures is headquartered in Cambridge, US.
Images
Co-investors · 4
Mission BioCapital provides early-stage capital and shared lab space to life science entrepreneurs, supporting companies from idea through clinic and exit.
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies focused on improving human health. It serves as Sanofi's entry point into the innovation ecosystem.
EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.
Cambridge Innovation Capital (CIC) is a UK-based venture capital firm backing entrepreneurs in life sciences and deep tech, leveraging its position in the Cambridge science and technology ecosystem.
Firms observed investing alongside MC Healthcare Ventures, from public investor directories. Shared companies are the overlap with MC Healthcare Ventures's recorded portfolio.
Similar investors
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Sofinnova is an investment firm that partners with biotech companies from inception through growth, supporting drug development, the regulatory process, company building, and IPO.
Kaiser Permanente Ventures is the corporate venture capital arm investing in healthcare companies that address real needs and deliver value for patients, providers, healthcare delivery systems, and communities.
Draper Associates is a venture capital firm that invests in technology startups across AI, robotics, blockchain, healthcare, aerospace, and frontier deep-tech fields.